AHP appoints former Ethicon Endo-Surgery President William Hawkins to lead medical device businesses.
This article was originally published in The Gray Sheet
Executive SummaryAHP'S NEW VP FOR MEDICAL DEVICE DIVISION WILLIAM HAWKINS faces the challenge of shoring up sales growth at the $1.3 bil. business while charting a course for the diversified giant's participation in the medical device field. American Home Products announced April 22 that it named Hawkins -- a former exec at Ethicon, Lilly, and Guidant -- to be Vice President for its Medical Device and Specialty Pharmaceutical Divisions. Hawkins will assume the post beginning April 28; he replaces David Lilley, who left AHP for Cytec in January.
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.